Introduction
BPC-157 is a synthetic pentadecapeptide sequence that has been investigated extensively in preclinical laboratory and animal research literature. This page summarizes published research context for laboratory professionals. It is not medical advice and does not authorize human use of research materials.
Chemical and structural summary
Catalog listing: BPC-157 Arginate, typically supplied as lyophilized powder (see product page for vial size). CAS commonly associated with the free peptide sequence: 137525-51-0. Identity and purity are lot-dependent; request a Certificate of Analysis for the lot you receive.
| Catalog name | BPC-157 Arginate |
|---|---|
| Category | Tissue and Repair Models |
| CAS | 137525-51-0 |
| Molecular weight note | About 1419.5 g/mol (free peptide; salt form may vary) |
| Documentation | Lot-specific CoA available on request |
Research history and background
BPC-157 (body protection compound-157) is described in the literature as a synthetic peptide derived from a partial sequence related to a protein found in gastric juice. Over several decades, experimental papers and reviews have examined this sequence in a range of animal and in vitro models. Systematic and narrative reviews emphasize that the bulk of the evidence base remains preclinical.
Areas investigated in laboratory and preclinical research
The following themes appear in peer-reviewed literature. Inclusion here means the topic has been studied or reviewed scientifically - not that catalog materials are validated for any endpoint.
- Soft-tissue and musculoskeletal injury models in animals (reviewed in orthopaedic and sports-medicine literature)
- Tendon and ligament experimental models discussed in narrative and systematic reviews
- Gastrointestinal mucosal and barrier-related animal models referenced across the BPC-157 literature corpus
- Angiogenesis and cytoprotective pathway hypotheses explored in preclinical reports
Mechanisms discussed in the literature
Reviews of preclinical work discuss proposed involvement of growth-related signaling, angiogenesis-associated pathways, and inflammatory-cytokine modulation in model systems. These mechanistic discussions are literature-derived hypotheses and model-level findings. They are not product claims and do not establish clinical indications for research reagents.
Key published studies and reviews
Prefer primary literature. Open links in a new tab. Always read full papers for methods and limitations.
- Gwyer D, et al. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. PubMed 30915550.
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (preclinical-focused synthesis). PubMed 40756949.
- Jozwiak M, et al. (2025). Multifunctionality and possible medical application of the BPC 157 peptide - literature and patent review. Pharmaceuticals. PubMed 40005999.
Known limitations and evidence gaps
High-quality, large-scale clinical trials remain limited relative to the volume of preclinical reports. Manufacturing quality, contamination risk, and regulatory status of non-pharmaceutical sources are repeatedly flagged as practical concerns in review literature. Findings in animal models do not automatically translate to humans. Always separate approved drug products (if any) from research-use materials sold for laboratory work.
Laboratory handling notes
General laboratory practice for lyophilized peptides includes cool, dry storage protected from moisture and light, careful reconstitution with appropriate research diluents, and documentation of lot numbers. See educational guides for process literacy - not product-specific validated stability claims.
- Storage and stability of lyophilized peptides
- Reconstitution best practices for laboratory use
- Reconstitution calculator (concentration and aliquot volume math)
- How to read a Certificate of Analysis
Regulatory status note
Materials sold by VialVibes are Research Use Only. They are not intended for human consumption, clinical administration, or veterinary use, and are not sold as FDA-approved drugs. Where the scientific literature discusses approved medicines or investigational drug programs involving the same active structure class, those regulated products remain distinct from RUO research reagents. See Research Use Only - what it means and the legal RUO policy.